Palvella Therapeutics Statistics
Want to see PVLA full AI Analyst Report?
Palvella Therapeutics (PVLA) Stock Statistics & Valuation Metrics
Total Valuation
Palvella Therapeutics has a market cap or net worth of $2.47B. The enterprise value is $1.97B.
- Market Cap
- $2.47B
- Enterprise Value
- $1.97B
Share Statistics
Palvella Therapeutics has 14,618,457 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 14,618,457
- Owned by Insiders
- 1.38%
- Owned by Institutions
- 43.17%
Financial Efficiency
Palvella Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -79.73%.
- Return on Equity (ROE)
- -1.49
- Return on Assets (ROA)
- -0.70
- Return on Invested Capital (ROIC)
- -79.73%
- Return on Capital Employed (ROCE)
- -0.80
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.44M
- Employee Count
- 29
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Palvella Therapeutics is -29.81. Palvella Therapeutics’s PEG ratio is 8.39.
- PE Ratio
- -29.81
- PS Ratio
- 0.00
- PB Ratio
- 12.04
- Price to FCF
- -55.65
- Price to Operating Cash Flow
- -55.32
- PEG Ratio
- 8.39
Income Statement
In the last 12 months, Palvella Therapeutics had revenue of 0 and earned -41.72M in profits. Earnings per share was -3.71.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -38.60M
- Pretax Income
- -41.72M
- Net Income
- -41.72M
- EBITDA
- -35.90M
- Earnings Per Share (EPS)
- -3.71
Cash Flow
In the last 12 months, operating cash flow was -43.06M and capital expenditures 0, giving a free cash flow of -43.06M billion.
- Operating Cash Flow
- -43.06M
- Free Cash Flow
- -43.06M
- Free Cash Flow per Share
- -2.96
Dividends & Yields
Palvella Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.80%
- Earnings Yield
- -3.15%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- 110.58%
- 50-Day Moving Average
- 142.69
- 200-Day Moving Average
- 129.33
- Relative Strength Index (RSI)
- 61.43
- Average Volume (3m)
- 237.08K
Important Dates
Palvella Therapeutics upcoming earnings date is Apr 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 05, 2027
- Ex-Dividend Date
- ―
Financial Position
Palvella Therapeutics as a current ratio of 5.20, with Debt / Equity ratio of 2.26%
- Current Ratio
- 5.20
- Quick Ratio
- 5.20
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.60
- Interest Coverage Ratio
- -6.63
Taxes
In the past 12 months, Palvella Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Palvella Therapeutics EV to EBITDA ratio is -30.53, with an EV/FCF ratio of -51.17.
- EV to Sales
- 0.00
- EV to EBITDA
- -30.53
- EV to Free Cash Flow
- -51.17
- EV to Operating Cash Flow
- -51.17
Balance Sheet
Palvella Therapeutics has $236.68M in cash and marketable securities with $485.00K in debt, giving a net cash position of $236.19M billion.
- Cash & Marketable Securities
- $236.68M
- Total Debt
- $485.00K
- Net Cash
- $236.19M
- Net Cash Per Share
- $16.16
- Tangible Book Value Per Share
- $13.62
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Palvella Therapeutics is $230.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $230.92
- Price Target Upside
- 40.85% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 10
- AI Score
- 62
